The Europe in vitro diagnostics market size is projected to expand at a substantial CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the wide prevalence of chronic diseases as well as growing public awareness regarding early detection of life-threatening diseases.
Medical devices, assays, and reagents are key components for in vitro diagnostics (IVD) process, which are used to diagnose a medical condition. Various instruments are also used to analyze tissue samples and bodily fluids obtained from patients and some of the key diagnostic instruments are immunodiagnostics, tissue diagnostics, and molecular diagnostics.
The diagnostics devices are also widely adopted for detecting various infectious diseases and chronic illness such as cardiac disorders, cancer, and diabetes. Furthermore, since the use and handling of in vitro diagnostics necessitates professional experience, diagnosis is carried out in specialist medical facilities using instruments. IVD materials, for example, are used in standalone labs, clinics, and point-of-care settings.
The elderly population is vulnerable to a variety of degenerative and infectious diseases, which is resulting in a wide occurrence of targeted diseases of this group of population. According to a report, the number of people aged 65 and above who are suffering from such diseases in Europe is projected to increase from 18.5 percent in 2014 to 28.7 percent in 2080. Since diagnostic interpretation is required for effective disease treatment, IVDs are important parts of the healthcare industry, especially in the diseases diagnosis.
Market Trends, Drivers, Restraints, and Opportunities
- Rising awareness among a large number of the global population for early diagnosis of life-threatening diseases represent a key driver for the market growth.
- Increasing number of the aging population globally and their higher chance for exposing to several infectious and chronic diseases is a major factor driving the market growth.
- Introduction of innovative technology that offers ease of use and effective diagnostic result along with several government policies for expansion of the healthcare infrastructure are pushing the market expansion at a significant rate.
- Availability of over-the-counter drugs and self-care diagnostic kits offering the items for home-setting treatment and point of care systems are reducing unnecessary physician or hospital visits. This is expected to boost the market growth.
- High cost for IVD treatment and lack of skilled technicians handling the diagnostic kits are some of the key challenges that can hamper the market revenue.
Scope of In Vitro Diagnostics Market Report
The report on the Europe in vitro diagnostics market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
Europe In Vitro Diagnostics Market - Industry Analysis, Growth, Share, Size, Trends, and Forecast
Products (Instruments, Reagents, and Services), Techniques (Immunology, Hematology, Clinical Chemistry, Coagulation, Microbiology, and Molecular Diagnostics), Applications (Infectious Disease, Diabetes, Cancer/Oncology, Cardiology, Autoimmune Disease, Nephrology, and Others), and End-users (Hospitals, Laboratories, and Home Care)
Germany, the UK, France, the Netherlands, and Rest of Europe
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
Key Players Covered in the Report
Roche Diagnostics; Alere, Inc.; Abbott Laboratories, Inc.; Hologic, Inc.; (Gen-Probe), Qiagen N.V.; Bio-Rad Laboratories, Inc.; Quidel Corporation; Becton, Dickinson (BD) Company Inc.; bioMerieux, Inc.; and Siemens Healthcare GmbH.
In Vitro Diagnostics Market Segment Insights
Reagent segment is expected to hold a dominant share
Based on products, the Europe in vitro diagnostics market is divided into instruments, reagents, and services. The reagent segment is expected to represent a key share of the market and hold a dominant share during the forecast period. The segment growth is attributed to increasingly adoption of reagent in clinical laboratories, academic medical schools, research centers, and therapeutic areas.
Molecular diagnostic segment is expected to grow at a rapid pace
On the basis of techniques, the market is divided into immunology, hematology, clinical chemistry, coagulation, microbiology, and molecular diagnostics. The molecular diagnostic segment is expected to grow at a rapid pace during the forecast period owing to its ability to diagnose various infectious and chronic diseases effectively and accurately. Moreover, the increasing market penetration of instrument manufacturers in Asia Pacific and Latin America presents a crucial aspect for the segment growth.
Oncology segment is anticipated to expand at a substantial CAGR
Based on applications, the Europe in vitro diagnostics market is divided into infectious disease, diabetes, cancer/oncology, cardiology, autoimmune disease, nephrology, and others. The cancer/oncology segment is expected to expand at a substantial CAGR during the forecast period due to the introduction of technologically advanced instruments and the increasing demand for companion diagnostics for various cancer treatment. Meanwhile, the infectious diseases diagnostics market is projected to account for a large market share in the coming years due to the increasing prevalence of hospital-acquired infections and the high unmet medical needs for successful infectious disease diagnosis.
Home care segment is anticipated to constitute a major share
In terms of end-users, the market is divided into hospitals, laboratories, and home care. The home care segment is anticipated to constitute a major share of the market during the forecast period. The segment growth can be attributed to growing demand for rapid diagnostic services for patients at the time of care and rising government measures aiming at reducing hospital stays in order to reduce healthcare spending. However, the hospitals segment is anticipated to exhibit a considerable growth rate during the projected period owing to high volume of IVD-based tests in hospitals.
The UK is a fast-growing market
On the basis of geography, the Europe in vitro diagnostics market is classified as Germany, the UK, France, the Netherlands, and Rest of Europe. The UK is a fast-growing market and is expected to hold a key market share during the forecast period owing to increasing demand for point-of-care and rapid-testing, especially blood glucose testing in the country. Moreover, the strong government support to encourage early disease detection for the prevention of infectious diseases among its citizens of the country plays an important role for the market development in the region. Germany, France, Italy, Spain, the UK, Belgium, Switzerland, Austria, the Netherlands, and Sweden accounted for more than 80% of the market share in 2020 owing to the involvement of a large number of main manufacturing firms such as Siemens Healthcare GmbH. Meanwhile, the high acceptance of these IVD technology in Germany is a major reason for owing for more than 15% of the regional market share in 2020.
The Europe in vitro diagnostics market has been segmented on the basis of
- Clinical Chemistry
- Molecular Diagnostics
- Infectious Disease
- Autoimmune Disease
- Home Care
- The UK
- The Netherlands
- Rest of Europe
- Roche Diagnostics
- Alere, Inc.
- Abbott Laboratories, Inc.
- Hologic, Inc.
- (Gen-Probe), Qiagen N.V.
- Bio-Rad Laboratories, Inc.
- Quidel Corporation
- Becton, Dickinson (BD) Company Inc.
- bioMerieux, Inc.
- Siemens Healthcare GmbH.
Key players competing in the Europe in vitro diagnostics market are Roche Diagnostics; Alere, Inc.; Abbott Laboratories, Inc.; Hologic, Inc.; (Gen-Probe), Qiagen N.V.; Bio-Rad Laboratories, Inc.; Quidel Corporation; Becton, Dickinson (BD) Company Inc.; bioMerieux, Inc.; and Siemens Healthcare GmbH. Market players are funding their research and development activities in order to develop advanced technology that helps to improve current diagnostic process.